KDR and gastric cancer: Monoclonal antibodies (such as HER2, VEGFR, or EGFR), multikinase inhibitors, and immune checkpoint inhibitor therapy (such as CTLA-4 or PD-1/PD-L1 are mainly involved in targeted therapy that has shown to be beneficial in the treating metastatic and advanced stages of GC patients (Seebacher et al., 2019).